Amplification and overexpression of FGFR2 can be availably detected in biopsy through IHC but also in liquid biopsy and surgical specimens, and they are consistently associated with aggressive tumor behavior, lower survival, and resistance to current therapy options, opening the way for directed treatment. The gene discussed is FGFR2; the disease is neoplasm.